12:00 AM
Jan 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ZD0473: Began Phase II trials

AnorMed Inc. (TSE:AOM), Vancouver, B.C.
Product: ZD0473
Business: Cancer
Therapeutic category: Cytotoxic...

Read the full 47 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >